HomeCompareCELP vs PFE

CELP vs PFE: Dividend Comparison 2026

CELP yields 1534.34% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CELP wins by $5.45M in total portfolio value
10 years
CELP
CELP
● Live price
1534.34%
Share price
$0.49
Annual div
$7.49
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.51M
Annual income
$41,615.09
Full CELP calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — CELP vs PFE

📍 CELP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCELPPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CELP + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CELP pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CELP
Annual income on $10K today (after 15% tax)
$130,419.21/yr
After 10yr DRIP, annual income (after tax)
$35,372.83/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, CELP beats the other by $12,243.87/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CELP + PFE for your $10,000?

CELP: 50%PFE: 50%
100% PFE50/50100% CELP
Portfolio after 10yr
$2.78M
Annual income
$34,412.82/yr
Blended yield
1.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CELP
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CELP buys
0
PFE buys
0
No recent congressional trades found for CELP or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCELPPFE
Forward yield1534.34%6.20%
Annual dividend / share$7.49$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$5.51M$51.1K
Annual income after 10y$41,615.09$27,210.54
Total dividends collected$3.79M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CELP vs PFE ($10,000, DRIP)

YearCELP PortfolioCELP Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$87,417$76,717.18$9,161$701.38+$78.3KCELP
2$406,920$313,383.17$8,610$859.79+$398.3KCELP
3$1,117,073$681,669.18$8,366$1,081.25+$1.11MCELP
4$2,069,714$874,445.84$8,483$1,405.66+$2.06MCELP
5$2,971,685$757,090.68$9,084$1,907.24+$2.96MCELP
6$3,687,659$507,956.48$10,418$2,732.78+$3.68MCELP
7$4,240,346$294,551.18$13,007$4,193.56+$4.23MCELP
8$4,695,440$158,269.62$18,010$7,005.87+$4.68MCELP
9$5,106,016$81,895.26$28,216$12,979.89+$5.08MCELP
10$5,505,053$41,615.09$51,081$27,210.54+$5.45MCELP

CELP vs PFE: Complete Analysis 2026

CELPStock

Cypress Environmental Partners, L.P. provides independent inspection, integrity, and support services in North America. The company operates in three segments: Inspection Services, Pipeline & Process Services (PPS), and Environmental Services. The Inspection Services segment offers inspection and integrity services on various infrastructure assets, including midstream pipelines, gathering systems, and distribution systems. This segment also provides various services, such as nondestructive examination, in-line inspection support, pig tracking, survey, data gathering, and supervision of third-party contractors. The PPS segment offers hydrostatic testing, chemical cleaning, water transfer and recycling, pumping, pigging, flushing, filling, dehydration, caliper runs, in-line inspection tool run support, nitrogen purging, and drying services, as well as test documentation and records retention services. The Environmental Services segment owns and operates 9 water treatment facilities with ten environmental protection agency class II injection wells in the Bakken shale region of the Williston Basin in North Dakota. This segment offers treatment, recovery, separation, and disposal of waste byproducts generated during the lifecycle of an oil and natural gas well to protect the environment and drinking water. The company serves owners and operators of pipelines and other infrastructure, public utility or local distribution, pipeline construction, oil and natural gas exploration and production, and trucking companies, as well as third-party purchasers of residual oil. Cypress Environmental Partners GP, LLC operates as the general partner of the company. The company was formerly known as Cypress Energy Partners, L.P. and changed its name to Cypress Environmental Partners, L.P. in March 2020. Cypress Environmental Partners, L.P. was founded in 2003 and is headquartered in Tulsa, Oklahoma.

Full CELP Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CELP vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CELP vs SCHDCELP vs JEPICELP vs OCELP vs KOCELP vs MAINCELP vs JNJCELP vs MRKCELP vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.